KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma

Current guidelines recommend two-drug cytotoxic chemotherapy with a fluoropyrimidine (fluorouracil or capecitabine) and a platinum-based agent (oxaliplatin or cisplatin) as first-line treatment for advanced gastric cancer. Pembrolizumab monotherapy has demonstrated durable antitumor activity in pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Tabernero, Josep, Bang, Yung-Jue, Van Cutsem, Eric, Fuchs, Charles S, Janjigian, Yelena Yuriy, Bhagia, Pooja, Li, Kan, Adelberg, David, Qin, Shu Kui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2021
Materias:
Clinical Trial Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892960/
https://www.ncbi.nlm.nih.gov/pubmed/33975465
http://dx.doi.org/10.2217/fon-2021-0176

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892960/
https://www.ncbi.nlm.nih.gov/pubmed/33975465
http://dx.doi.org/10.2217/fon-2021-0176

Ejemplares similares